11 July 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusivity agreement with a US-based specialty pharmaceutical company in connection with the potential out-licensing of ReNeuron’s hRPC retinal stem cell technology and therapeutic programmes.